Long Grove Pharmaceuticals is a generics manufacturer specializing in providing complex formulation generics with challenging manufacturing and supply chain dynamics. Long Grove Pharmaceuticals will begin shipping its first products in 2022. The first commercial product launch will be Triamcinolone Acetonide Injection Suspension, USP. This product is an AB rated suspension, TAA compliant, and is manufactured in the EU. It will be available in 1 mL single-dose vials and 5 mL and 10 mL multiple dose vials.